Chantix
(Varenicline Tartrate)Phase 3Small molecule
PfizerVarenicline Tartrate is used to help people quit smoking by reducing cravings and blocking the rewarding effects of nicotine in the brain.[1] Chantix is currently being investigated across 3 indications[3], with its most advanced program in Phase 3.[1]
Chantix is one of 53 small molecule programs targeting Smokers. It is currently in Phase 3.
3
Indications
23
Total Trials
2
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
45 competitors in Nicotine Dependence
#DrugCompanyPhaseTrials
1Nicorette
PfizerApproved
Ritalin
NovartisApproved
Revia
TevaApproved
Aricept
EisaiApproved
Epidiolex
Jazz PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Rozerem
TakedaApproved
Namenda
AbbVieApproved
Lioresal
NovartisApproved
Lopid
PfizerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Absorption4 trials
Smoking Cessation3 trials
Smokers3 trials
Psychiatric Disorder2 trials
9 more indications
Effectiveness1 trial
Tobacco Use Disorder1 trial
Efficacy1 trial
Safety and Efficacy1 trial
Chronic Obstructive Pulmonary Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Varenicline Tartrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]